An update on some of the companies in attendance on September 13-14:
Otsuka Pharmaceutical Development and Commercialization, Inc., Acorda Therapeutics, GSK, CSL Behring, Forest Research Institute, Zalicus, Structural Genomics Consortium, Janssen R&D, NASA, Sanofi, Hepregen, Eli Lilly and Company, EnVivo Pharmaceuticals, Inc, STC Biologics, AstraZeneca, Brigham and Women’s Hospital | Harvard Medical School, Momenta Pharmaceuticals, MPM Capital, Novartis, Pfizer, Purdue Pharma, Merck, Shire, J&J, Genzyme, Endo, Vertex Pharmaceuticals, MHRA, Millenium, The Takeda Oncology Company, Baxter, Boehringer Ingelheim USA, AMAG Pharma, Biogen Idec, Celtic Pharma, Radius Pharma, Theravance Inc., Rib-X Pharmaceuticals, Alliance for Clinical Research Excellence and Safety, ACRES, Cerexa, Inc., Esperion Therapeutics, Merck Sharp & Dohme, Janssen Pharmaceutical Companies of Johnson & Johnson, Center for Medical Technology Policy, Bill & Melinda Gates Foundation, Alexion Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Rhythm Pharmaceuticals, Milestone Ventures Partners, Bristol Myers Squibb, Celtic Therapeutics, REATA Pharmaceuticals, Geisinger Health System, SK Biopharmaceuticals SK Life Sciences, Cubist Pharmaceuticals, Onyx Pharmaceuticals, Millenium Pharmaceuticals,
For more information contact service@theconferenceforum.org.
For more information on the Agenda visit here.
For 10% off the registration fee use code BLOG.
